Skip to content
Log in
Sponsored Design Multi-Agent AI Systems Using MCP and A2A: Engineer your own Pyt Design Multi-Agent AI Systems Using MCP and A2A: Engineer your own Pyt

Efficacy Is Impacted by

Celina García-García M. Rivas Y. Ibrahim M. Calvo Albert Gris-Oliver O. Rodríguez J. Grueso Pilar Antón M. Guzman C. Aura P. Nuciforo Katti A. Jessen G. Argilés R. Dienstmann A. Bertotti L. Trusolino J. Matito A. Vivancos I. Chicote Héctor G. Palmer J. Tabernero M. Scaltriti J. Baselga V. Serra
· 0 citations · 27 references

TL;DR

Dual MEK and mTORC1/2 blockade resulted in synergistic antiproliferative effects in cell lines bearing alterations in KRAS/BRAF and PIK3CA/PTEN and a marked proapoptotic response to therapy was observed exclusively in wild-type TP53 colorectal cancer models.

Semantic Scholar
View source

Similar papers

Sep 2026

Abstract B087: Impact of RAS inhibition on T cell maturation in the PDAC microenvironment

It is suggested that pharmacologic and genetic KRAS inhibition differentially remodel the intratumoral T cell compartment, whereas both induce similar T cell changes within the liver premetastatic niche.

Lauren Gerbereux, Rashmi Kumar, E. Lasse-Opsahl et al. · 0 citations

RICTOR/mTORC2 downregulation in BRAF

This work unveils an unforeseen tumor-suppressing role for mTORC2 in the early adaptation phase of BRAF V600E melanoma cells to targeted therapy and identifies the NAMPT-ETC axis as a potential therapeutic vulnerability of low RICTOR tumors.

Ponzone Luca Prof, V. Calautti, Ssa Federica Cavallo · 0 citations
Sep 2026

Abstract PR012: Encoding adaptive mechanisms of resistance to KRAS inhibition in pancreatic cancer

This study defines adaptive resistance mechanisms to KRAS-targeted therapy in PDAC, revealing both cell-state-dependent RTK rewiring and a conserved SFK adaptive signaling axis and provides a mechanistic rationale for either KRAS/pan-RAS or pan-RAS/SFK co-inhibition as strategies to improve responses to KRAS-targeted t...

Qing-Xiang Lin, Bo-Kai Song, C. Sander et al. · 1 citation
Aug 2026

Therapeutic targeting of RAS-mediated resistance in oncogene-driven lung cancer.

RAS alterations mediate resistance to targeted agents in approximately 10% of oncogene-driven lung cancer, and Rational combinations with novel RAS inhibitors are effective in preclinical models, providing the basis for their clinical investigation and extending the paradigm of precision oncology.

F. Facchinetti, L. Friboulet, L. Liao et al. · 0 citations
Open access Sep 2026

Systematic Evaluation of Combination Strategies with Rezatapopt in p53 Y220C-Mutant Cancer Models.

Rezatapopt (PC14586), a first-in-class Y220C-selective p53 reactivator, demonstrates single-agent clinical efficacy; however, combinatorial strategies may enhance clinical outcomes. Here, we evaluated rezatapopt in combination with standard-of-care agents (chemotherapy and bevacizumab), murine double minute 2 (MDM2) in...

Tamer Ahmed, Erin E. Michaud, Li-Zhong Xu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.